Skip to main content

Zoetis Inc (ZTS) Stock

Zoetis Inc Stock Details, Movements and Public Alerts

Stock Details

Zoetis Inc (ZTS), a prominent company in the healthcare sector within the drug manufacturers - specialty & generic industry, is based in USA and primarily trades on the NYSE.Currently, the stock is trading at $144.40. Over the past 52 weeks, it has ranged between $138.76 and $181.33. This places the current price at 79.6% of its 52-week high and 4.1% above its 52-week low. Recent trading volume was recorded at 688,599. The 14-day Relative Strength Index (RSI) stands at 45.10, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $147.65 by 2.20%. Similarly, it is below its 200-day moving average of $156.32 by 7.63%. The MACD histogram is 0.36, indicating bullish momentum (MACD Line: -0.23, Signal Line: -0.59). The International Securities Identification Number (ISIN) for this stock is US98978V1035. There is currently 1 active alert set for ZTS by users.

52-Week Range

$181.33 - $138.76

-20.37% from high · +4.06% from low

Avg Daily Volume

2,766,547

20-day average

100-day avg: 3,001,648

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

24.53

Near market average

Forward P/E

21.69

Earnings expected to grow

PEG Ratio

2.19

Potentially overvalued

Price to Book

13.04

EV/EBITDA

17.49

EPS (TTM)

$5.80

Price to Sales

6.72

Beta

0.90

Less volatile than market

How is ZTS valued relative to its earnings and growth?
Zoetis Inc trades at a P/E ratio of 24.53, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 21.69 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 2.19 indicates a premium valuation even accounting for growth.
What is ZTS's risk profile compared to the market?
With a beta of 0.90, Zoetis Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 13.04 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

27.80%

Operating Margin

40.60%

EBITDA

$3.96B

Return on Equity

52.80%

Return on Assets

15.40%

Revenue Growth (YoY)

4.20%

Earnings Growth (YoY)

17.50%

How profitable and efficient is ZTS's business model?
Zoetis Inc achieves a profit margin of 27.80%, meaning it retains $27.80 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 40.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 52.80% and ROA at 15.40%, the company generates strong returns on invested capital.
What are ZTS's recent growth trends?
Zoetis Inc's revenue grew by 4.20% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 17.50% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against DRUG MANUFACTURERS - SPECIALTY & GENERIC industry averages for proper context.

Dividend Information

Dividend Per Share

$1.86

Dividend Yield

1.32%

Ex-Dividend Date

Oct 31, 2025

Dividend Date

Dec 2, 2025

What dividend income can investors expect from ZTS?
Zoetis Inc offers a dividend yield of 1.32%, paying $1.86 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of Oct 31, 2025.
How reliable is ZTS's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Zoetis Inc pays $1.86 per share in dividends against earnings of $5.80 per share, resulting in a payout ratio of 32.14%. This balanced payout between 30-60% suggests a sustainable dividend policy that allows both shareholder returns and business reinvestment. The dividend appears well-covered by earnings. The next dividend payment is scheduled for Dec 2, 2025.

Company Size & Market

Market Cap

$63.0B

Revenue (TTM)

$9.38B

Revenue/Share (TTM)

$20.90

Shares Outstanding

443.18M

Book Value/Share

$11.21

Asset Type

Common Stock

What is ZTS's market capitalization and position?
Zoetis Inc has a market capitalization of $63.0B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 443.18M shares outstanding, the company's ownership is relatively concentrated. As a participant in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry, it competes with other firms in this sector.
How does ZTS's price compare to its book value?
Zoetis Inc's book value per share is $11.21, while the current stock price is $144.40, resulting in a price-to-book (P/B) ratio of 12.88. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$189.15

30.99% upside potential

Analyst Recommendations

Strong Buy

5

Buy

8

Hold

5

Sell

0

Strong Sell

0

How reliable are analyst predictions for ZTS?
18 analysts cover ZTS with 72% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $189.15 implies 31.0% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on ZTS?
Current analyst recommendations:5 Strong Buy, 8 Buy, 5 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 15, 2025, 02:30 AM

Technical Indicators

RSI (14-day)

45.10

Neutral

50-Day Moving Average

$147.65

-2.20% below MA-50

200-Day Moving Average

$156.32

-7.63% below MA-200

MACD Line

-0.23

MACD Signal

-0.59

MACD Histogram

0.36

Bullish

What does ZTS's RSI value tell investors?
The RSI (Relative Strength Index) for ZTS is currently 45.10, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
How should traders interpret ZTS's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.23 above the signal line at -0.59, with histogram at 0.36. This bullish crossover suggests upward momentum is building. The 50-day MA ($147.65) is below the 200-day MA ($156.32), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Oct 30, 2025, 12:40 AM

Active Alerts

Alert Condition
Price falls below
Threshold
$135.00
Created
Oct 3, 2025, 08:26 AM

Stay Ahead of the Market with Zoetis Inc Alerts

Set up price alerts for Zoetis Inc and get notified instantly when the price hits your target. Never miss an important price movement again.